Rotavirus vaccines and vaccination in Latin America

Revista Panamericana de Salud Publica/Pan American Journal of Public Health

Volumn 8, Issue 5, 2000, Pages 305-331

  Linhares, A C ^a   Bresee, J S ^a  

^a FUNDAÇÃO NACIONAL DE SAÚDE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSID PROTEIN; RHESUS HUMAN REASSORTANT ROTAVIRUS VACCINE; ROTAVIRUS VACCINE; SIMIAN ROTAVIRUS VACCINE; UNCLASSIFIED DRUG;

DIARRHEAL DISEASE; DISEASE CONTROL; VACCINATION; VIRAL DISEASE;

ACUTE DIARRHEA; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; FEVER; HOST SUSCEPTIBILITY; HUMAN; INFANTILE DIARRHEA; INFECTION PREVENTION; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; ROTAVIRUS; STRAIN DIFFERENCE; VACCINE PRODUCTION; VIRUS INFECTION;

LATIN AMERICA;

EID: 0034528410     PISSN: 10204989     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1020-49892000001000002     Document Type: Article

References (248)

1. The magnitude of the global problem of diarrhoeal disease: A ten-year update
2. The magnitude of the global problem of acute diarrhoeal disease: A review of active surveillance data
3. From Rwanda to Wisconsin: The global relevance of diarrhoeal diseases
4. Incidence and etiology of infantile diarrhea and major routes of transmission in Huascar, Peru
5. Longitudinal studies of infectious diseases and physical growth of infants in Huascar, an underprivileged periurban community in Lima, Peru
6. A prospective study of persistent diarrhea among children in urban Brazilian slums. Patterns of occurrence and etiologic agents
7. Low endemicity and low pathogenicity of rotaviruses among rural children in Costa Rica
8. Infant mortality in southern Brazil: A population based study of causes of death
9. A study of infant mortality and causes of death in a rural north-east Brazilian community
10. Program for diarrheal disease control in Cali, Colombia
11. Mortality due to intestinal infectious diseases in Latin America and the Caribbean, 1965-1990
12. Diarrhoeal diseases control programme: An overview of the problem in the Americas
13. Interventions for the control of diarrhoeal diseases among young children: Supplementary feeding programmes
14. Why promote breast-feeding in diarrhoeal disease control programmes
15. Viral gastroenteritis
16. Acute diarrhea in Baltimore children attending an outpatient clinic
17. Virus particles in epithelial cells of duodenal mucosa from children with viral gastroenteritis
18. Global seasonality of rotavirus infections
19. Rotaviruses
20. The prospects for immunizing against rotavirus
21. Policy analysis of the use of hepatitis B, Haemophilus influenzae type B-, Streptococcus pneumoniae-conjugate and rotavirus vaccines in national immunization schedules
22. Interventions for the control of diarrhoeal diseases among young children: Rotavirus and cholera immunization
23. Development of candidate rotavirus-vaccines
24. The structure of the rotavirus inner capsid studied by electron microscopy of chemically disrupted particles
25. Rotavirus epidemiology in Vellore, South India: Group, subgroup, serotype, and electrophoretype
26. Passive protection against rotavirus-induced diarrhea by monoclonal antibodies to the heterotypic neutralization domain of VP7 and the VP8 fragment of VP4
27. Human immunity to rotavirus
28. Homotypic serum antibody responses to rotavirus proteins following primary infection of young children with serotype 1 rotavirus
29. Homotypic and heterotypic epitope-specific antibody response in adult and infant rotavirus vaccinees: Implications for vaccine development
30. Comparison of serum and mucosal antibody responses following severe acute rotavirus gastroenteritis in young children
31. Relative concentrations of serum neutralizing antibody to VP3 and VP7 proteins in adults infected with a human rotavirus
32. Localization of VP4 neutralization sites in rotavirus by three-dimensional cryo-electron microscopy
33. Three dimensional structure of rhesus rotavirus by cryoelectron microscopy and image reconstruction
34. Passive protection against rotavirus-induced diarrhea by monoclonal antibodies to surface proteins VP3 and VP7
35. Proteolytic enhancement of human rotavirus infectivity
36. Rotavirus vaccine development for the prevention of severe diarrhea in infants and young children
37. Age-dependent diarrhea induced by a rotaviral nonstructural glycoprotein
38. Introduction: Rotavirus-from basic research to a vaccine
39. Production and preliminary characterization of monoclonal antibodies directed at two surface proteins of rhesus rotavirus
40. Rotavirus gene structure and function
41. Antigenic relationships among human rotaviruses as determined by outer capsid protein VP4
42. Review of G and P typing results from a global collection of rotavirus strains: Implications for vaccine development
43. Relative frequency of VP4 gene alleles among human rotaviruses recovered over a 10-year period (1982-1991) from Japanese children with diarrhea
44. Distribution of VP4 gene alleles among human rotaviruses by using probes to the hyperdivergent gene of the VP4 gene
45. Detection and characterization of novel rotavirus strains in the United States
46. Rotavirus-like agent in adult non-bacterial diarrhoea in China
47. Waterborne outbreak of rotavirus diarrhoea in adults in China caused by a novel rotavirus
48. Detection of group C rotavirus in infants with extrahepatic biliary atresia
49. Group B and C rotaviruses
50. Viral agents of gastroenteritis. Public health importance and outbreak management
51. Human rotavirus studies in volunteers: Determination of infectious dose and serological response to infection
52. Serial observations of chronic rotavirus infection in an immunodeficient child
53. Intestinal damage in rotavirus and adenovirus gastroenteritis assessed by d-xylose malabsorption
54. Transmissible gastroenteritis: Sodium transport in the intestinal epithelium during the course of viral enteritis
55. Histologische befunde der dunndarmschleimhaut bei rotavirusinfektionen im sauglings-und kleinkindalter
56. Role of the enteric nervous system in the fluid and electrolyte secretion of rotavirus diarrhea
57. Rotavirus gastroenteritis
58. Group A rotaviruses
59. Cohort study of rotavirus serotype patterns in symptomatic and asymptomatic infections in Mexican children
60. Intestinal permeability changes in acute gastroenteritis: Effects of clinical factors and nutritional management
61. Fecal adenoviruses from a longitudinal study of families in metropolitan Washington, D.C.: Laboratory, clinical and epidemiologic observations
62. Oral rehydration therapy for acute diarrhea in ambulatory children in the United States: A doubleblind comparison of four different solutions
63. Effect of malnutrition on rotavirus infection in mice
64. Seroepidemiological study of rotavirus infection in rural Ghana
65. Etiology of acute diarrhoea among children in developing countries: A multicentre study in five countries
66. Protection from rotavirus infection: 2-year prospective study
67. Risk of diarrhoea during the first year of life associated with initial and subsequent colonization by specific enteropathogens
68. Longitudinal study of rotavirus infections among children from Belém, Brazil
69. The Tecumseh study. XV. Rotavirus infection and pathogenicity
70. Neonatal rotavirus infections
71. Rotaviruses as a cause of nosocomial, infantile diarrhoea in Northern Brazil
72. Nosocomial rotaviral diarrhea: Pattern of spread on wards in a children's hospital
73. Use of electrophoresis of RNA from human rotavirus to establish the identity of strains involved in outbreaks in a tertiary care nursery
74. Longitudinal studies of infectious diseases and physical growth of children in rural Bangladesh II. Incidence of diarrhoea and association with known pathogens
75. The impact of rotavirus disease in Venezuela
76. Longitudinal study of rotavirus infection and gastroenteritis in families served by a pediatric medical practice: Clinical and epidemiological observations
77. Rotavirus infection in children hospitalized for diarrhoea in Argentina
78. Identificación de enteropatógenos en la diarrea de la infancia y un estudio realizado en la ciudad de Posadas, Misiones, República Argentina
79. Acute enteritis associated with rotavirus presen in Brazilian children: Evaluations on prevalence, therapy and age group
80. Electrophoretic study of the genome of human rotavirus from Maceió, Brazil
81. Acute diarrhoea associated with rotavirus among children living in Belém, Brazil
82. Rotavirus viral RNA electrophoresis in hospitalized infants with diarrhea in Santiago, Chile
83. Enteropathogens associated with acute diarrhea in hospitalized infants
84. Comparison of human rotavirus disease in tropical and temperate settings
85. Epidemiology of rotaviruses in a cohort of 45 Guatamalan Mayan Indian children observed from birth to the age of three years
86. Rotavirus infection in children with acute gastroenteritis in Ecuador
87. Prospective study of enteropathogens in children with diarrhea in Houston and Mexico
88. Diarrea infantil aguda por rotavirus en una población pediátrica de Mérida, Yucatán, México
89. Epidemiology of rotavirus infection and gastroenteritis in prospectively monitored Argentine families with young children
90. Acute diarrhoeal disease in children under 7 years of age in a peri-urban slum of Santiago, Chile
91. Temporal and geographical distribution of human rotavirus serotypes, 1983 to 1988
92. Prevalence and serotype specificity of rotavirus antibodies in different age groups of Ecuadorian infants
93. Serotyping of human rotaviruses in Argentina by ELISA with monoclonal antibodies
94. Frecuencia de serotipos G de rotavirus aislados de niños con diarrea en Mérida, Yucatán, México
95. Epidemiology of rotavirus subgroups and serotypes in Belém, Brazil: A three-year study
96. Culture adaptation and characterization of group A rotaviruses causing diarrheal illnesses in Bangladesh from 1985 to 1986
97. Temporal distribution of human rotavirus serotypes 1, 2, 3 and 4 in Venezuelan children with gastroentedtis during 1979-1989
98. Rotavirus serotype G5 associated with diarrhea in Brazilian children
99. Rotavirus G and P types circulating in Brazil: Characterization by RT-PCR, probe hybridization, and sequence analysis
100. Survey of rotavirus G and P types associated with human gastroenteritis in São Paulo, Brazil, from 1986 to 1992
101. Clinical immunity after neonatal rotavirus infection: A prospective, longitudinal study in young children
102. Mechanisms of protection against rotavirus in humans and mice
103. Infection immunity of piglets to either VP3 or VP7 outer capsid protein confers resistance to challenge with a virulent rotavirus bearing the corresponding antigen
104. Serum neutralizing-antibody titers compared by plaque reduction and enzyme-linked immunosorbent assay-based neutralization assays
105. Host defense mechanisms at mucosal surfaces
106. Immunoglobulin A (IgA): Molecular and cellular interactions involved in IgA biosynthesis and immune response
107. Protection conferred by neonatal rotavirus infection against subsequent rotavirus diarrhea
108. Evaluation of WC3 rotavirus vaccine correlates of protection in healthy infants
109. Protective effect of naturally acquired homotypic and heterotypic rotavirus antibodies
110. Sequential rotavirus infections: Characterization of serotypes and electropherotypes
111. An observational study of naturally acquired immunity to rotaviral diarrhea in a cohort of 363 Egyptian children. Calculation of risk for second episodes using age-specific person-years of observation
112. Rotavirus infection in infants as protection against subsequent infections
113. Neutralizing antibody immune response in children with primary and secondary rotavirus infections
114. Group- and type-specific serologic response in infants and children with primary rotavirus infections and gastroenteritis caused by a strain of known serotype
115. Identification of VP7 epitopes associated with protection against human rotavirus illness or shedding in volunteers
116. Anti-rotavirus G type-specific and isotype-specific antibodies in children with natural rotavirus infections
117. Comparison of rotavirus immunoglobulin A coproconversion with other indices of rotavirus infection in a longitudinal study in childhood
118. Seroepidemiologic evaluation of antibodies to rotavirus as correlates of risk of clinically significant rotavirus diarrhea in rural Bangladesh
119. Role of coproantibody in clinical protection of children during reinfection with rotavirus
120. Fecal antibody responses to symptomatic and asymptomatic rotavirus infections
121. Vaccines for enteric viral pathogens
122. Host factors associated with protection against rotavirus disease: The skies are clearing
123. Rotavirus-specific cytotoxic T lymphocytes cross-react with target cells infected with different rotavirus serotypes
124. Recovery from chronic rotavirus infection in mice with severe combined immunodeficiency: Virus clearance mediated by adoptive transfer of immune CD8+ T lymphocytes
125. Molecular determinants of immunity and pathogenicity of rotavirus infection in the mouse model
126. A case for cytokines as effector molecules in the resolution of virus infection
127. Maternal antibody-mediated protection against gastroenteritis due to rotavirus in newborn mice is dependent on both serotype and titer of antibody
128. Antibody to human rotavirus in cow's milk
129. The effects of maternal antibodies on neonatal rotavirus infection
130. Human milk mucin inhibits rotavirus replication and prevents experimental gastroenteritis
131. Breastfeeding and the risk of life-threatening rotavirus diarrhea: Prevention or postponement?
132. Effects of antibodies, trypsin and trypsin inhibitors on susceptibility of neonates to rotavirus infection
133. Prevention of human rotavirus induced diarrhea in gnotobiotic piglets using bovine antibody
134. Rotavirus vaccine: Success by reassortment?
135. Rotavirus infection in lambs: Studies on passive protection
136. Advances in molecular biology: Impact on rotavirus vaccine development
137. Immunity to neonatal calf diarrhea virus
138. Diarrhea associated with rotavirus in rural Guatemala. A longitudinal study of 24 infants and young children
139. Protective effect of WC3 vaccine against rotavirus diarrhea in infants during a predominantly serotype 1 rotavirus season
140. Independent segregation of two antigenic specificities (VP3 and VP7) involved in neutralization of rotavirus infectivity
141. Immunogenicity and safety of live oral attenuated bovine rotavirus vaccine strain RIT 4237 in adults and young children
142. Protection of infants against rotavirus diarrhoea by RIT 4237 attenuated bovine rotavirus strain vaccine
143. Neonatal rotavirus vaccination with PIT 4237 bovine rotavirus vaccine: A preliminary report
144. Clinical efficacy of the RIT 4237 live attenuated bovine rotavirus vaccine in infants vaccinated before a rotavirus epidemic
145. Trial of an attenuated bovine rotavirus vaccine (RIT 4237) in Gambian infants
146. Failure of live, attenuated oral rotavirus vaccine
147. A field study of the safety and efficacy of two candidate rotavirus vaccines in a Native American population
148. Protection of Peruvian children against rotavirus diarrhea of specific serotypes by one, two, or three doses of the RIT 4237 attenuated bovine rotavirus vaccine
149. Immune response of infants and children to low-passage bovine rotavirus (strain WC3)
150. The development of multivalent bovine rotavirus (strain WC3) reassortant vaccine for infants
151. Reactogenicity and immunogenicity of rotavirus WC3 vaccine in 5-12 month old infants
152. Evaluation of the efficacy of a low passage bovine rotavirus in children in Central Africa
153. Antigenic comparisons of two new rotaviruses from rhesus monkeys
154. Selection of cold-adapted mutants of human rotaviruses that exhibit various degrees of growth restriction in vitro
155. VP4 protein of porcine rotavirus strain OSU expressed by a baculovirus recombinant induces neutralizing antibodies
156. Development of a diploid cell line from fetal rhesus monkey lung for virus vaccine production
157. Efficacy of quadrivalent rhesus rotavirus-based human rotavirus vaccine aimed at preventing severe rotavirus diarrhea in infants and young children
158. An update on the "Jennerian" and modified "Jennerian" approach to vaccination of infants and young children against rotavirus diarrhea
159. Reactogenicity and antigenicity of the rhesus rotavirus vaccine in Venezuelan children
160. Immunogenicity, safety and protective efficacy of one dose of the rhesus rotavirus vaccine and serotype 1 and 2 human-rhesus rotavirus reassortants in children from Lima, Peru
161. Safety, infectivity, transmissibility and immunogenicity of rhesus rotavirus vaccine (MMU 18006) in infants
162. Oral rotavirus vaccination in breast- and bottle-fed infants aged 6 to 12 months
163. Evaluation of a candidate rotavirus vaccine (rhesus rotavirus strain) in children
164. Evaluation of rhesus rotavirus monovalent and tetravalent reassortant vaccines in US children
165. Field trial of rhesus rotavirus vaccine in infants
166. Safety, immunogenicity, and protective efficacy of one and three doses of the tetravalent rhesus rotavirus vaccine in infants in Lima, Peru
167. Field trial of rhesus rotavirus or human-rhesus rotavirus reassortant vaccine of VP7 serotype 3 or 1 specificity in infants
168. Prolonged efficacy of rhesus rotavirus vaccine in Swedish children
169. Prospective study of diarrheal diseases in Venezuelan children to evaluate the efficacy of rhesus rotavirus vaccine
170. Efficacy of rhesus rotavirus vaccine MMU-18006 against gastroenteritis due to serotype 1 rotavirus
171. Immune protection of infants against rotavirus gastroenteritis by a serotype 1 reassortant of bovine rotavirus WC3
172. Reassortant rotaviruses as potential live rotavirus candidate vaccines
173. Rotavirus vaccines: An overview
174. Evaluation of the protective efficacy of a serotype 1 bovine-human rotavirus reassortant vaccine in infants
175. The outer capsid protein VP4 of murine rotavirus Eb represents a tentative new P type Virology
176. Preliminary evaluation of safety and efficacy of quadrivalent human-bovine reassortant rotavirus vaccine
177. Safety and immunogenicity of live attenuated human-bovine (UK) reassortant rotavirus vaccines with VP7-specificity for serotypes 1, 2, 3 or 4 in adults, children and infants
178. Single gene substitution rotavirus reassortants containing the major neutralization protein (VP7) of human rotavirus serotype 4
179. Protective efficacy against serotype 1 rotavirus diarrhea by live oral rhesus-human reassortant rotavirus vaccines with human rotavirus VP7 serotype 1 or 2 specificity
180. Comparison of immunogenicity and efficacy of rhesus rotavirus reassortant vaccines in breastfed and nonbreastfed children
181. Lack of correlation between serum rotavirus antibody titers and protection following vaccination with reassortant RRV vaccines
182. Safety and immunogenicity of oral tetravalent humanrhesus reassortant rotavirus vaccine in neonates
183. Comparison of reactogenicity of M37 rotavirus vaccine and rhesus-rotavirus-based quadrivalent vaccine
184. Immunogenicity of tetravalent rhesus rotavirus vaccine administered with buffer and oral poliovirus vaccine
185. Evaluation of the antigenicity and reactogenicity of varying formulations of the rhesus rotavirus-based quadrivalent and the M37 rotavirus vaccine candidates
186. Safety and efficacy of high-dose rhesushuman reassortant rotavirus vaccines - Report of the National Multicenter Trial
187. Efficacy and safety of high-dose rhesus-human reassortant rotavirus vaccine in Native American populations
188. A comparative evaluation of the safety and immunogenicity of a single dose of unbuffered oral rhesus/human reassortant serotypes 1, 2 and 4 and combined (tetravalent) vaccines in healthy infants
189. Randomised placebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis
190. Review of rotavirus vaccine trials in Finland
191. Immunogenicity, safety and efficacy of rhesus-human, reassortant rotavirus vaccine in Belém, Brazil
192. Reappraisal of the Peruvian and Brazilian lower titer tetravalent rhesus-human reassortant rotavirus vaccine efficacy trials: Analysis by severity of diarrhea
193. Efficacy of the rhesus rotavirus-based quadrivalent vaccine in young children in Venezuela
194. Intussusception among recipients of rotavirus vaccine - United States, 1998-1999
195. Possible association of intussusception with rotavirus vaccination
196. Withdrawal of rotavirus vaccine recommendation
197. Lack of apparent association between intussusception and wild or vaccine rotavirus infection
198. Tetravalent humanrhesus reassortant rotavirus vaccine: A review of its immunogenicity, tolerability and protective efficacy against paediatric rotavirus gastroenteritis
199. Human rotavirus infection in infants and young children with intussusception
200. A two-part study of the aetiological role of rotavirus in intussusception
201. A one-year virological survey of acute intussusception in childhood
202. Safety and immunogenicity of human rotavirus vaccine strain M37 in adults, children and infants
203. Efficacy of two doses of RIT 4237 bovine rotavirus vaccine for prevention of rotavirus diarrhoea
204. An epidemic of diarrhea in human neonates involving a reoviruslike agent and "enteropathogenic" serotypes of Escherichia coli
205. Efficacy of live, attenuated, human rotavirus vaccine 89-12 in infants: A randomised placebo-controlled trial
206. Cold-adaptation of human rotavirus
207. Assessment of intestinal damage in rotavirus infected neonatal mice by a D-xylose absorption test
208. Prevention of rotavirus induced diarrhea in neonatal mice born to dams immunized with empty capsids of simian rotavirus SA11
209. Vaccinia virus recombinants expressing the SA11 rotavirus VP7 glycoprotein gene induce serotype-specific neutralising antibodies
210. Expression of rotavirus VP7 antigens in fusions with bacterial proteins
211. Rotavirus vaccines and vaccination potential
212. Vaccinia-rotavirus VP7 recombinants protect mice against rotavirus-induced diarrhoea
213. The immunogenicity of VP7, a rotavirus antigen resident in the endoplasmic reticulum, is enhanced by cell surface expression
214. Virus-like particles as rotavirus subunit vaccine
215. Characterization of virus-like particles produced by the expression of rotavirus capsid proteins in insect cells
216. Synthesis and immunogenicity of the rotavirus major capsid antigen using a baculovirus expression system
217. Vaccines for the Third World
218. Protective immunity to rotavirus-induced diarrhoea is passively transferred to newborn mice from naive dams vaccinated with a single dose of a recombinant adenovirus expressing rotavirus VP7sc
219. Expression of the OSU rotavirus outer capsid protein VP4 by adenovirus recombinant
220. Rotavirus neutralizing protein VP7: Antigenic determinants investigated by sequence analysis and peptide synthesis
221. Priming for rotavirus neutralizing antibodies by a VP4 protein-derived synthetic peptide
222. Engineering of immunogenic peptides by co-linear synthesis of determinants recognized by B and T cells
223. Protection against rotavirus infections by DNA vaccination
224. Protection of ferrets against influenza challenge with a DNA vaccine to haemagglutinin
225. Effect of maternal rotavirus immunization on milk and serum antibody titers
226. Influence of breast-feeding and oral poliovirus vaccine on the immunogenicity and efficacy of rotavirus vaccines
227. Immune response to rotavirus vaccine among breastfed and nonbreast-fed children
228. Effect of breast-feeding on oral rhesus rotavirus vaccine seroconversion: A metaanalysis
229. Take of rhesus-human reassortant rotavirus vaccine in breast-fed infants
230. Combined vaccination with live oral polio vaccine and the bovine rotavirus RIT 4237 strain
231. Interference of oral poliovirus vaccine on RIT 4237 oral rotavirus vaccine
232. Simultaneous administration of rhesus rotavirus vaccine and oral poliovirus vaccine: Immunogenicity and reactogenicity
233. Immunogenicity and reactogenicity of rhesus rotavirus vaccine given in combination with oral or inactivated poliovirus vaccine and diphtheria-tetanus-pertussis vaccine
234. Concurrent oral poliovirus and rhesushuman reassortant rotavirus vaccination effects on immune responses to both vaccines and on efficacy of rotavirus vaccines
235. Influence of breast-feeding and oral poliovirus vaccine on the immunogenicity and efficacy of rotavirus vaccines
236. Simultaneous administration of oral rhesus-human reassortant tetravalent (RRV-TV) rotavirus vaccine and oral poliovirus vaccine (OPV) in Thai infants
237. Factors affecting the immunogenicity of oral poliovirus vaccine: A prospective evaluation in Brazil and Gambia
238. Evaluating new vaccines for developing countries. Efficacy or effectiveness
239. Economic impact of immunization against rotavirus gastroenteritis
240. Cost-effectiveness analysis of a rotavirus immunization program for the United States
241. Cost-effectiveness analysis of a rotavirus immunization program for the United States
242. Current status and future priorities for rotavirus vaccine development, evaluation and implementation in developing countries
243. Rotavirus vaccines-from licensure to disease reduction
244. Selected regulatory and scientific topics for candidate rotavirus vaccine development
245. Points to consider in the manufacture and testing of monoclonal antibody products for human use